Conditions: Her2 Amplified Solid Tumors Metastatic Breast Cancer
Keywords: Her2 amplified solid tumors Breast Cancer Her3/ErbB3 Bispecific Antibody
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 20
Healthy volunteers: no

Brief summary:
This study is an open-label Phase 1 trial of MM-111.

Detailed description:
Phase 1: Patients with any solid tumor type may be enrolled to evaluate the safety and tolerability of MM-111.

Arms:
arm 1: None

Interventions: intervention 1: MM-111
Intervention descriptions: intervention 1: For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV

Protocol document: